GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine injection) 100 Units/ml for $35.
This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect Jan. 1, 2024. It leverages GoodRx’s reach and scale to broaden access and affordability for people living with diabetes and means that all Americans with a valid prescription, regardless of insurance status, can use GoodRx at more than 70,000 U.S. retail pharmacies to access a 30-day supply of Lantus.
The number of Americans living with diabetes increases every year. Currently, an estimated 37.3 million Americans (approximately 11.3% of the U.S. population) have diabetes, and roughly 8.4 million of them use insulin, according to the American Diabetes Association.
[Read more: GoodRx unveils Medicine Cabinet]
“Efforts to make insulin more accessible have been at the forefront of the news for months, and a critical piece of delivering on this promise is making it as simple as possible for patients to get the lower price right at their regular pharmacy counter," said Dorothy Gemmell, chief commercial officer at GoodRx. "Sanofi is taking action and providing Americans who need insulin with the ability to access Lantus in an easy and affordable way, regardless of insurance status. We’re proud to collaborate with them on this initiative.”
Patients can visit GoodRx.com/lantus to access the $35 price coupon, which can be redeemed at any pharmacy that accepts GoodRx, including CVS, Walgreens and Walmart. This complements other savings programs already offered by Sanofi, including offering Lantus for $35 per month to people without insurance. GoodRx also offers supportive resources to help consumers holistically manage their condition, including discounts on continuous glucose monitors and coupons for diabetes medications, as well as a Diabetes Hub that offers diabetes-specific articles and resources written by medical experts.
“Sanofi believes that no one should struggle to pay for their insulin,” said Olivier Bogillot, head of U.S. general medicines at Sanofi. “We are proud to collaborate with GoodRx to build on our existing suite of industry-leading savings programs to expand access and affordability pathways that can bring convenient and meaningful impact at the pharmacy counter.”